The treatment of hormone refractory prostate cancer.
Panvichian
R
R
Michigan Prostate Institute, University of Michigan Comprehensive Cancer Center, Ann Arbor 48109-0680, USA.
Pienta
K J
KJ
D000726:Androgen Antagonists / Q000627:therapeutic use; D000970:Antineoplastic Agents / Q000627:therapeutic use*; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D004961:Estramustine / Q000008:administration & dosage / Q000627:therapeutic use; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D009919:Orchiectomy; D011379:Prognosis; D011471:Prostatic Neoplasms / Q000473:pathology / Q000628:therapy*; D013498:Suramin / Q000627:therapeutic use; D014747:Vinblastine / Q000008:administration & dosage / Q000627:therapeutic use
D000726:Androgen Antagonists; D000970:Antineoplastic Agents; D004961:Estramustine; D014747:Vinblastine; D013498:Suramin